Denis Grizelj

Denis Grizelj is the CEO and Co-Founder of MD Labs.  With a degree in business management, Denis is responsible for overseeing the business operations of Rxight that are associated with billing and insurance authorizations.  Of all the services MD Labs offers, the Rxight pharmacogenetic test is one that Denis is incredibly passionate about.  He has seen the benefits of Rxight as it has helped members of his family with their medication management, avoiding dangerous ADRs. 

The experience of bringing Rxight to the market has been a rewarding one and was highlighted by a visit to the White House and speaking to the Office of Science and Technology Policy in 2016.  Denis, Matthew Rutledge, and other key members of the MD Labs team were invited to speak to the staff about Rxight and pharmacogenetics within the Precision Medicine Initiative.

Denis is excited about the future of Rxight and the role of pharmacogenetics in healthcare.  Healthcare Providers are seeing the value and importance in the data Rxight provides and it helps them make important decisions on their patients’ medications and dosage. 

Denis stays current on all of the latest news and trends in the pharmacogenetics industry which allow for MD Labs to continue to optimize Rxight and make it the best pharmacogenetic test offering on the market. Connect via LinkedIn.